Ra Capital Management as of March 31, 2020
Portfolio Holdings for Ra Capital Management
Ra Capital Management holds 48 positions in its portfolio as reported in the March 2020 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Ascendis Pharma A S (ASND) | 17.5 | $554M | 4.9M | 112.61 | |
| Ra Pharmaceuticals | 7.4 | $233M | 4.9M | 48.01 | |
| Chemocentryx | 5.3 | $168M | 4.2M | 40.18 | |
| Arvinas Ord (ARVN) | 4.7 | $148M | 3.7M | 40.30 | |
| Zogenix | 4.1 | $131M | 5.3M | 24.73 | |
| Axsome Therapeutics (AXSM) | 3.5 | $112M | 1.9M | 58.83 | |
| Eidos Therapeutics | 3.3 | $106M | 2.2M | 48.99 | |
| Tg Therapeutics (TGTX) | 3.2 | $102M | 10M | 9.84 | |
| Satsuma Pharmaceuticals Ord | 3.2 | $101M | 4.7M | 21.52 | |
| Alector (ALEC) | 3.1 | $100M | 4.1M | 24.13 | |
| Phathom Pharmaceuticals (PHAT) | 3.0 | $96M | 3.7M | 25.82 | |
| Kala Pharmaceuticals | 3.0 | $96M | 11M | 8.79 | |
| Rhythm Pharmaceuticals (RYTM) | 2.6 | $83M | 5.4M | 15.22 | |
| 89bio (ETNB) | 2.5 | $80M | 3.2M | 25.25 | |
| Exelixis (EXEL) | 2.5 | $78M | 4.5M | 17.22 | |
| Wave Life Sciences (WVE) | 2.3 | $73M | 7.8M | 9.37 | |
| Adverum Biotechnologies | 2.2 | $71M | 7.3M | 9.77 | |
| Momenta Pharmaceuticals | 2.2 | $69M | 2.5M | 27.20 | |
| Black Diamond Therapeutics (BDTX) | 2.0 | $65M | 2.6M | 24.95 | |
| Retrophin | 1.9 | $61M | 4.2M | 14.59 | |
| Orchard Therapeutics Plc ads | 1.8 | $57M | 10M | 5.50 | |
| Igm Biosciences (IGMS) | 1.7 | $55M | 983k | 56.15 | |
| Verastem | 1.6 | $49M | 19M | 2.64 | |
| Relmada Therapeutics (RLMD) | 1.5 | $47M | 1.4M | 34.11 | |
| Gilead Sciences (GILD) | 1.3 | $41M | 548k | 74.76 | |
| Prevail Therapeutics Ord | 1.2 | $40M | 3.2M | 12.19 | |
| Ardelyx (ARDX) | 1.2 | $37M | 6.4M | 5.68 | |
| Arcutis Biotherapeutics (ARQT) | 1.1 | $35M | 1.2M | 29.80 | |
| Adaptimmune Therapeutics (ADAP) | 1.1 | $34M | 13M | 2.72 | |
| Crinetics Pharmaceuticals In (CRNX) | 0.9 | $29M | 2.0M | 14.70 | |
| Scpharmaceuticals (SCPH) | 0.8 | $26M | 3.5M | 7.40 | |
| Trillium Therapeutics, Inc. Cmn | 0.8 | $26M | 6.4M | 4.04 | |
| Stoke Therapeutics (STOK) | 0.8 | $26M | 1.1M | 22.90 | |
| Imara | 0.7 | $23M | 1.5M | 16.03 | |
| Compugen (CGEN) | 0.7 | $22M | 3.0M | 7.26 | |
| ImmunoGen | 0.6 | $18M | 5.2M | 3.41 | |
| Novocure Ltd ord (NVCR) | 0.6 | $17M | 259k | 67.34 | |
| Concert Pharmaceuticals I equity | 0.5 | $16M | 1.9M | 8.84 | |
| Solid Biosciences | 0.3 | $11M | 4.6M | 2.39 | |
| Galera Therapeutics (GRTX) | 0.3 | $8.5M | 893k | 9.50 | |
| X4 Pharmaceuticals (XFOR) | 0.2 | $6.0M | 602k | 10.00 | |
| Passage Bio (PASG) | 0.2 | $5.1M | 323k | 15.75 | |
| Uniqure Nv (QURE) | 0.1 | $3.9M | 82k | 47.44 | |
| Essa Pharma (EPIX) | 0.1 | $3.8M | 959k | 4.00 | |
| Portola Pharmaceuticals | 0.1 | $3.1M | 429k | 7.13 | |
| Selecta Biosciences | 0.1 | $2.1M | 871k | 2.41 | |
| Insmed (INSM) | 0.0 | $1.4M | 87k | 16.03 | |
| Vericel (VCEL) | 0.0 | $917k | 100k | 9.17 |
